Andrew J. Antczak, Ph.D., advises clients on strategic development and monetization of patent portfolios in the areas of life science, digital health, and computer-implemented technologies. Andrew regularly counsels clients on a range of issues overlapping business and intellectual property concerns, including competitive intelligence, freedom to operate opinions, transactional due diligence, and post-grant proceedings, and has experience assisting clients defend and prosecute European opposition matters. He currently sits on the firm’s digital health steering committee.
Informed by his scientific background in biochemistry, molecular biology, genetics, and structural biology, Andrew represents clients ranging from global pharma/biopharmaceutical and medical device companies to machine-learning bioinformatics and consumer electronic corporations.
Prior to joining Morgan Lewis, Andrew was a patent scientist at a national law firm, where his work included drafting and prosecuting patents, freedom to operate diligence, and providing patent litigation support. As part of his dissertational work, Andrew studied histone chaperones and their role in chromosome assembly, replication, and remodeling, using biochemical, genetic, and structural biology approaches, including elucidation of the X-ray crystallographic structure of two histone chaperones. As an undergraduate, he studied regulatory control of DNA replication initiation.
Golden Gate University School of Law, 2017, J.D., Lani Bader Award
University of California, Berkeley, 2007, Ph.D. (Molecular and Cell Biology)
Michigan State University, 2001, B.S. (Biochemistry/Biotechnology), With High Honors
US Patent and Trademark Office
Awards and Affiliations
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Member, Litigation Department of the Year–Intellectual Property, The American Lawyer (2019)